Asplenia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Asplenia}} | {{Asplenia}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Anum Dilip}} | ||
==Overview== | ==Overview== | ||
Line 26: | Line 26: | ||
{{WS}} | {{WS}} | ||
[[Category:Medicine]] | |||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Primary care]] | |||
[[Category:Immunology]] | |||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category: | [[Category:Emergency medicine]] |
Revision as of 02:49, 30 June 2020
Asplenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Asplenia secondary prevention On the Web |
American Roentgen Ray Society Images of Asplenia secondary prevention |
Risk calculators and risk factors for Asplenia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anum Dilip, M.B.B.S[2]
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]